Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Advertisement

Advertisement




Jan
16
Today In Oncology
Triplet Therapy Demonstrates Superior Progression-Free Survival in First-Line dMMR-MSI-H Metastatic Colorectal Cancer
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer
HER2-Positive Gastroesophageal Cancer Zanidatamab Plus Chemotherapy Prolongs Progression-Free Survival
Improved Contralateral Breast Cancer Risk Knowledge With Personalized Counseling Tool
Machine Learning–Guided Optical Biopsy Accurately Identifies Malignant Lung Nodules Intraoperatively
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo